Cancer therapy

A prostate cancer and vaccine technology, applied in the field of cancer therapy, can solve problems such as non-certification of use

Pending Publication Date: 2018-11-23
MADISON VACCINES INC
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These recent advances have clearly improved the situation for patients with advanced prostate cancer; however, recent advances have also presented new challenges with regard to the optimal sequence and approach to manage castration-resistant disease
Despit

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer therapy
  • Cancer therapy
  • Cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0239] Example 1 - The role of PD-1 in patients who previously received the PAP vaccine

[0240] Although DNA vaccines elicit antigen-specific CD8+ T cells in humans, persisting over a timescale of approximately years, the persistence of antigen-expressing tumors suggests that tumor escape mechanisms are at work. For example, data collected in human trials indicates that some patients show no signs of an immune response, and even those who do still show signs of disease progression. Therefore, to improve the immunological activity of DNA vaccines (eg, in the development of DNA vaccines for the treatment of prostate cancer), experiments were performed during the development of embodiments of the technology to collect data related to the mechanism of tumor resistance.

[0241] To assess the role of PD-1 in patients who previously received a DNA vaccine encoding PAP. Specifically, similar to previously reported studies, experiments were performed using a delayed-type hypersensit...

Embodiment 2

[0243] Example 2 - Results of co-administration of pembrolizumab and pTVG in patients with castration-resistant metastatic prostate cancer- Clinical results obtained with the HP DNA vaccine

[0244] This example presents results obtained from co-administration of pembrolizumab and pTVG-HP DNA vaccine to patients with castration-resistant metastatic prostate cancer. Briefly, patients in the trial were divided into two groups. The first arm (concurrent arm) received concurrent administration of pembrolizumab and pTVG-HP DNA vaccine on day 1, followed by subsequent administration of pembrolizumab every 3 weeks thereafter, and subsequent administration of pTVG-HP DNA every 2 weeks thereafter Vaccine up to 10 weeks. The second cohort (sequential cohort) received pTVG-HP DNA vaccine every 2 weeks for a total of 10 weeks, followed by pembrolizumab every 3 weeks starting at week 12 until week 21. The schedule of administration is outlined in figure 1 middle. Results: Although tr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein is technology relating to cancer treatment and prevention and particularly, but not exclusively, to compositions and methods related to therapies for prostate cancer.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Application 62 / 294,349, filed February 12, 2016, and US Provisional Application 62 / 404,252, filed October 5, 2016, each of which is incorporated herein by reference in its entirety. [0003] Statement Regarding Federally Funded Research or Development [0004] This invention was made with government support under Grant No. W81XWH-08-1-0341 awarded by the Department of Defense and Grant No. CA 142608 awarded by the National Institutes of Health. The government has certain rights in this invention. technical field [0005] Provided herein are technologies pertaining to cancer treatment and prevention, and particularly, but not exclusively, pertaining to compositions and methods related to prostate cancer therapy. Background technique [0006] Prostate cancer is the most common tumor in men and the second leading cause of cancer-related death in men in the United Sta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K39/395C12N15/09
CPCA61K2039/505A61K2039/53A61K2039/545C07K16/2818C07K16/3069C07K2317/24C07K2317/76A61P35/04A61P35/00A61K39/001193A61K39/0011A61K39/001163A61K2039/884A61K39/3955A61K2039/55516
Inventor 道格·麦克尼尔理查德·莱斯尼夫斯基
Owner MADISON VACCINES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap